Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.47 -1.26 (-0.80%)
Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The S&P 500 Had Its Worst July in a Decade. Should You Really Buy Stocks Now?
It's key to take a long-term view. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
These two healthcare companies have far more upside potential than Johnson & Johnson. 
Via The Motley Fool
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
Abbott Laboratories' growth rate may look comparable to Johnson & Johnson's, but in the long run it could become much higher. 
Via The Motley Fool
Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment. 
Via InvestorPlace
A Closer Look at 14 Analyst Recommendations For Johnson & Johnson
Via Benzinga
Johnson & Johnson Unusual Options Activity For July 29
Via Benzinga
7 Leading MedTech Stocks for Next-Gen Health Solutions
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar. 
Via InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
Q3’s Rising Stars: 3 Dow Stocks for Your Must-Watch List
These Dow stocks to watch have all been beaten down over the past year or more but are now poised for a rebound. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Check Out What Whales Are Doing With JNJ
Via Benzinga
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July. 
Via MarketBeat
Topics ETFs
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
From Johnson & Johnson
Via Business Wire
Stocks Going Ex Dividend In August 2024
A short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors. 
Via Talk Markets
7 Long-Term Stocks to Buy on the Dip: July 2024
As investors begin to rotate out of tech stocks, it's time to look at these long-term stocks that are trading at an inviting discount. 
Via InvestorPlace
Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?
Is it safe to buy Johnson & Johnson stock now? 
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
From Beasley Allen Law Firm
Via Business Wire
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
From Ad Hoc Group of Counsel
Via Business Wire
3 Stocks Reeling From Ruined Reputations: Can They Recover?
Unforced errors by each of these controversial stocks has sullied their reputations and recovering them will not be easy or cheap. 
Via InvestorPlace
3 Beaten-Down Value Stocks Poised for a Massive Comeback: July 2024
Investors might want to consider these beaten-down value stocks, each of which looks poised for a turnaround in the year's second half. 
Via InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Via Benzinga
Exposures Product Safety
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his record and support Medicare for All. 
Via Benzinga
Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
Intuitive Surgical is an AI stock that you can buy and hold forever. Its business is health care; it makes profits, and health care is growing 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
From Beasley Allen Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.